You are here

Home » Content

HEMODİALİZ HASTALARINDA YÜKSEK DOZ 1.25 (OH)2 KOLEKALSİFEROL UYGULAMASI VE KULLANILAN DEĞİŞİK MEMBRANLARIN SERUM PARATİROİD HORMON (PTH) DÜZEYİ ÜZERİNE ETKİSİ

1.25 (OH)2 CHOLECALCIFEROL PULSE THERAPY AND THE EFFECTS OF DIFFERENT DIALYSIS MEMBRANES ON SERUM PTH LEVELS OF HEMODIALYSIS PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1995

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
30 patients, 10 female, 20 male has been included in this study. In 15 cases high-flux polysulfon and in 15 patients cuprophan membranes are used. Ca ion level of dialisate was 1.5 mmollL for both groups. Following one month of therapy with 0.07 mglkg and six months of therapy with 0.03 mglkg, three times a week, PTH, Alkaline Phosphatase and ionized Ca levels were significantly normal. CaCO^ was used with the dose of 3 gr/day as a phosphate binding agent. As a result, we believe for the treatment of secondary hyperparathyroidism the intermittent oral calcitriol pulse therapy depending on body weight, low dialisate calcium and using biocompatible membranes due to their high permeability and high PTH clearance are very effective, safe and a better choice.
Bookmark/Search this post with
Abstract (Original Language): 
Yirmi erkek, 10 kadın toplam 30 hasta bu çalışmaya dahil edilmiştir. Onbeş hastada highflux polysul-fon ve 15 hastada cuprophan membranlar kullanıl¬mıştır. Her iki grupta dializatın kalsiyum ion seviyesi 1.5 mmollL idi. Bir aylık 0.07mglkg calcitrol tedavisini takiben 6 ay uygulanan 0.03 mglkglhaftada 3 kez calcitrol tedavisinden sonra PTH, alkalen fosfataz ve ionize Ca kan seviyeleri belirgin olarak normal idi. CaCOs gri gün dozunda fosfat bağlayıcı ajan olarak kullanıldı. Sonuç olarak; sekonder hiperparatiroidizm tedavisinde vücut ağırlığına bağlı olarak aralıklı oral calcitrol pulse tedavisi ve düşük dializat kalsiyumu ve yüksek permeabilitesinden dolayı yüksek PTH klirensi olan biouyumlu membran kullanımının son derece et¬kili, güvenli ve iyi bir seçim olduğunu düşünüyoruz
FULL TEXT (PDF): 
PDF icon pdf_tndt_87.pdf
  • 2
91-96
  • Turkish

REFERENCES

References: 

1. Cburn JW, Llach F. Renal osteodystrophy and maintenance dialysis in replacement of renal function by dialy¬sis Drucker W, Parsous FM, Maher CF (eds), Martinus. Nijhoff publishers Dortrecht 1990; p 679.
2. Ahmet KY, Varghesse Z, Wills MR. Long-term effect of small doses of 1.25 (OH)2 cholecalciferol in renal os-
teodystrophy. Lancet 1978; i: 629-632.
3. Madsen S, Olgoard K. Long-term trial of 1 alfa hydroxycholecalciferol in adults with chronic renal fai¬lure. Eur J Clin Pharmacol 1970; 13: 401-408.
4. Cherrad DJ, Coburn JW, Brickman AS. Skeletal respon¬se to treatment with 1.25 (OH)2 cholecalciferol in renal failure. Contrib Nephrol 1980; 18: 92-97.
5. Cantley LK, Russel KJ, Lettieri D. 1.25 (OH)2 cholecal-
ciferol supresses parathyroid hormone secretion from parathyroid cells in tissue culture. Endocrinology 1975; 117:2114-2119.
6. Russel J, Lettieri D, Sherwood LH. Suppression by 1.25 (OH)2 cholecalciferol of transcription of the parathyroid hormone gene. Endocrinology 1986; 119: 2864-2866.
7. Silver J, Naveb-Many T, Mayer H. Regulation by vita¬min D metabolites of parathyroid hormone gene trans¬cription in vivo in the rat. J Clin Invest 1986; 78: 1296¬1301.
8. Slatopolsky E, Weerts C, THielan J, et al. Marked supp¬ression of secondary hyperparathyroidism by intraveno¬us administration of 1.25 (OH)2 cholecalferol in uremic
patients. J Clin Invest 1984; 74: 2136-2143.
95
9. Dunlay R, Rodriguez M, Felsenfelt AJ, Llach F. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int 1989; 36: 1093-1098.
10. Delmez JA, Tindra C, Grooms P, et al. Parathyroid hormone suppression by intravenous 1.25 (OH)2 cholecalci-ferol. A role for increased sensitivity to calcium. J Clin Invest 1989; 83: 1349-1355.
11. Fukagawa M, Okazaki R, Takanu K, et al. Regression of parathyroid hyperplasia by calcitriol pulse therapy in pa¬tients on long term dialysis. N Engl J Med 1990; 323:
421426.
12. Kwan JTC, Almound MK, Beer JC et al. Pulse oral cal-citriol in uremic patients: Rapid modification of parath¬yroid response to calcium. Nephrol Dial Transplant 1992; 7: 829-834.
13. Andress DL, Norris KC, Coburn JW et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl Med 1989; 321: 274-279. '
14. Fischer ER, Harris DCh. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clinical Nephro-logy 1993; 40: 216-220.
15. Tsukamoto Y, Nomura M, Kikawada R, et al. The oral 1.25 (OH)2 cholecalciferol pulse theray in hemodilaysis patients with severe secondary hyperparathyroidism. Nephron 1991; 57: 23-28.
16. Muramoto H, Haruki K, Yoshimura A, et al. Treatment of refractory hyperparathyroidism in patients on hemo-dialysis by intermittent oral administration of 1.25
(OH)2 cholecalciferol. Nephron 1991; 58: 288-294.
17. Malberti F, Sunan M, Cosci P. Improvement of secon-dery hyperparathyroidizm and reduction of the set point of calcium after intravenous calcitriol. Kidney Int 1993;
43 (suppl. 41): 125-130.
18. Aim de Francisko M, Prieto JA, Amado SC, et al. Dialy¬sis membranes and PTH changes during hemodialysis.
Nephrol Dial Transpl (abst.) 1992; 7: 753.
19. Fernandes E, Bertlu Ma, Cao G, et al. Hyperphosphate-mia stimulates PTH secretion by a direct, calcium inde¬pendent mechanism. Nephrol Dial Transpl (abst.) 1993;
7: 767.
20. Moriniere Ph, Esper N El, Viron B, et al. Improvement of severe secondary hyperparathyroidism in dialysis pa¬tients by intravenous 1 a (OH) cholecalciferol oral cal¬cium carbonate and low dialysate calcium. Kidney Int 193; 43 (suppl. 41): 121-124.
21. Klehr HH, Hristea D, Klein B, Paar D. Treatment of se¬vere secondary hyperparathyroidism with oral calcitriol pulse therapy depending on body weight. Nephrol Dial
Transpl 1992; 7: 760 (abstract).
22. Van der Merve WM, Rodger RS C, Grant AC, et al.
Low calcium dialysate and high dose oral calcitriol in the treatment of secondary hyperparathyroidism in he-modialysis patients. Nephrol Dial Transpl 1990; 5: 874¬877.
23. Massry SG, Golstein DA, Malluche HH. Current status of the use of 1.25 (OH)2 cholecalciferol in the manage¬ment of renal osteodystrophy. Kidney Int 1980; 18: 409¬419.
24. Pierides AM, Ellis HA, Dellagrammatikas H, et al. 1.25
(OH)2 cholecalciferol in renal osteodystrophy. Arch Dis
Child 1972; 52: 464472.
25. Klaus G, Mebls O, Flinderer J, Ritz E. Is Intermittent oral calcitriol safe and effective in renal secondary
hyperparathyroidism ? Lancet 1991; 337: 800-801.
96

Thank you for copying data from http://www.arastirmax.com